Ignite Creation Date:
2024-05-06 @ 10:27 AM
Last Modification Date:
2024-10-26 @ 12:30 PM
Study NCT ID:
NCT03264547
Status:
UNKNOWN
Last Update Posted:
2017-09-21
First Post:
2017-08-01
Brief Title:
A Study to Compare Eribulin Mesylate Pertuzumab Trastuzumab With Paclitaxel or Docetaxel Pertuzumab Trastuzumab
Sponsor:
Japan Breast Cancer Research Group
Organization:
Japan Breast Cancer Research Group
Study Overview
Official Title:
A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate Pertuzumab Trastuzumab With Paclitaxel or Docetaxel Pertuzumab Trastuzumab EMERALD
Status:
UNKNOWN
Status Verified Date:
2017-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To verify that combination therapy with trastuzumab pertuzumab eribulin brings similar PFS and better QOL compared to trastuzumab pertuzumab taxane in advancedrecurrent HER2-positive breast cancer patients who have no medical history of chemotherapy except ado-trastuzumab emtansine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None